Monte Rosa Therapeutics, Inc. (GLUE)
GLUE Stock Price Chart
Explore Monte Rosa Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze GLUE price movements and trends.
GLUE Company Profile
Discover essential business fundamentals and corporate details for Monte Rosa Therapeutics, Inc. (GLUE) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
24 Jun 2021
Employees
142.00
Website
https://www.monterosatx.comCEO
Markus Warmuth
Description
Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines. Their core approach involves leveraging the body's inherent mechanisms to precisely eliminate therapeutically relevant proteins. Among their key initiatives is an oral molecular glue degrader designed to target GSPT1, a specific translational termination factor and degron-containing protein, with the aim of treating Myc-driven cancers. The company's pipeline further includes programs for CDK2 in ovarian, uterine, and breast cancers, alongside NEK7 for addressing a spectrum of inflammatory conditions such as Crohn's disease, neurodegenerative ailments, diabetes, and liver disease. Moreover, VAV1 is being explored as a target for autoimmune disorders, and BCL11A, a protein holding significant therapeutic relevance, is under investigation for hemoglobinopathies. Founded in 2019, Monte Rosa Therapeutics, Inc. operates from its headquarters in Boston, Massachusetts.
GLUE Financial Timeline
Browse a chronological timeline of Monte Rosa Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Aug 2026
EPS estimate is -$0.37, while revenue estimate is $12.91m.
Earnings released on 7 May 2026
EPS came in at -$0.45 falling short of the estimated -$0.28 by -60.71%, while revenue for the quarter reached $4.20m , missing expectations by -61.65%.
Earnings released on 17 Mar 2026
EPS came in at -$0.54 falling short of the estimated -$0.35 by -53.61%, while revenue for the quarter reached $2.80m , missing expectations by -82.00%.
Earnings released on 6 Nov 2025
EPS came in at -$0.33 surpassing the estimated -$0.37 by +9.92%, while revenue for the quarter reached $12.77m , missing expectations by -17.66%.
Earnings released on 7 Aug 2025
EPS came in at -$0.15 surpassing the estimated -$0.38 by +60.19%, while revenue for the quarter reached $23.19m , beating expectations by +198.37%.
Earnings released on 8 May 2025
EPS came in at $0.57 surpassing the estimated -$0.00 by +21.69k%, while revenue for the quarter reached $84.93m , beating expectations by +526.01%.
Earnings released on 20 Mar 2025
EPS came in at $0.23 surpassing the estimated $0.02 by +1.38k%, while revenue for the quarter reached $60.65m , beating expectations by +29.95%.
Earnings released on 7 Nov 2024
EPS came in at -$0.29 surpassing the estimated -$0.49 by +40.82%, while revenue for the quarter reached $9.22m , beating expectations by +249.34%.
Earnings released on 8 Aug 2024
EPS came in at -$0.43 surpassing the estimated -$0.54 by +20.37%, while revenue for the quarter reached $4.70m , beating expectations by +248.07%.
Earnings released on 9 May 2024
EPS came in at -$0.53 surpassing the estimated -$0.57 by +7.02%, while revenue for the quarter reached $1.06m , missing expectations by -24.00%.
Earnings released on 14 Mar 2024
EPS came in at -$0.58 falling short of the estimated -$0.33 by -75.76%.
Earnings released on 9 Nov 2023
EPS came in at -$0.70 surpassing the estimated -$0.72 by +2.78%.
Earnings released on 10 Aug 2023
EPS came in at -$0.71 falling short of the estimated -$0.70 by -1.43%.
Earnings released on 11 May 2023
EPS came in at -$0.65 surpassing the estimated -$0.68 by +4.41%.
Earnings released on 16 Mar 2023
EPS came in at -$0.63 falling short of the estimated -$0.62 by -1.61%.
Earnings released on 10 Nov 2022
EPS came in at -$0.58 surpassing the estimated -$0.60 by +3.33%.
Earnings released on 11 Aug 2022
EPS came in at -$0.57 falling short of the estimated -$0.54 by -5.56%.
Earnings released on 11 May 2022
EPS came in at -$0.51 surpassing the estimated -$0.52 by +1.92%.
Earnings released on 29 Mar 2022
EPS came in at -$0.93 falling short of the estimated -$0.50 by -86.00%.
Earnings released on 10 Nov 2021
EPS came in at -$0.43 surpassing the estimated -$0.44 by +2.27%.
Earnings released on 12 Aug 2021
EPS came in at -$3.63 falling short of the estimated -$0.40 by -807.50%.
GLUE Stock Performance
Access detailed GLUE performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
